MRK Stock Recent News

EXEL rides on Cabometyx momentum and pipeline gains, while MRK leans on Keytruda dominance and a diverse portfolio for growth.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that new clinical trial and outcomes research data will be presented at the European Society of Cardiology Congress (ESC) 2025 in Madrid, Spain from August 29 – September 1. Data presented at ESC include Merck's latest research focusing on atherosclerotic cardiovascular disease (ASCVD), pulmonary hypertension (PH), and heart failure with reduced ejection fraction (HFrEF). “Cardiovas.

The Dow Jones Industrial Average (DJIA) is one of the oldest and most widely recognized stock market indices in the world.

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung cancer.

MRK banks on Keytruda's soaring sales and new oncology strategies to fuel 2025 growth, even as competition and patent loss loom.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced results from a new global survey revealing significant gaps in pet owner adherence to flea and tick prevention and concerns among veterinarians, underscoring the need for year-round protection. According to Pet Owner & Vet Perspectives on Parasite Treatment and Prevention: A Global Survey, t.

I reiterate my buy rating on Merck, citing its attractive valuation and improving technicals despite sector headwinds. Merck's recent earnings beat was driven by strong oncology and cardiovascular portfolios, offsetting Gardasil weakness and Keytruda patent concerns. The stock offers a solid 4% dividend yield, low PEG ratio, and consistent growth, making it appealing for income and value investors.

Merck trades at a single-digit P/E, reflecting underperformance but strong financials and a robust dividend yield near 3.9%. Keytruda's ongoing success and expanded indications drive near-term results, but loss of exclusivity looms in three years. Merck's pipeline and Verona acquisition position it to offset Keytruda revenue loss, with $50B+ mid-2030s opportunity projected.

Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back.